ZA966698B - Use of PDE inhibitors in the treatment of urinary bladder diseases. - Google Patents

Use of PDE inhibitors in the treatment of urinary bladder diseases.

Info

Publication number
ZA966698B
ZA966698B ZA9606698A ZA966698A ZA966698B ZA 966698 B ZA966698 B ZA 966698B ZA 9606698 A ZA9606698 A ZA 9606698A ZA 966698 A ZA966698 A ZA 966698A ZA 966698 B ZA966698 B ZA 966698B
Authority
ZA
South Africa
Prior art keywords
treatment
urinary bladder
pde inhibitors
bladder diseases
diseases
Prior art date
Application number
ZA9606698A
Other languages
English (en)
Inventor
Michael Carsten Trus
Stefan Ueckert
Christian Georg Stief
Wolf-Georg Forssmann
Udo Jonas
Original Assignee
Wolf George Forssmann Prof
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wolf George Forssmann Prof filed Critical Wolf George Forssmann Prof
Publication of ZA966698B publication Critical patent/ZA966698B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9606698A 1995-08-08 1996-08-07 Use of PDE inhibitors in the treatment of urinary bladder diseases. ZA966698B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19529102A DE19529102A1 (de) 1995-08-08 1995-08-08 Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen

Publications (1)

Publication Number Publication Date
ZA966698B true ZA966698B (en) 1998-02-09

Family

ID=7768971

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606698A ZA966698B (en) 1995-08-08 1996-08-07 Use of PDE inhibitors in the treatment of urinary bladder diseases.

Country Status (9)

Country Link
EP (1) EP0843553A1 (xx)
JP (1) JP2000501698A (xx)
AU (1) AU6702596A (xx)
CA (1) CA2228314A1 (xx)
DE (1) DE19529102A1 (xx)
EA (1) EA199800192A1 (xx)
HU (1) HUP0104619A3 (xx)
WO (1) WO1997005876A1 (xx)
ZA (1) ZA966698B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6417208B1 (en) * 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2549480B2 (ja) * 1991-12-10 1996-10-30 ヘキストジャパン株式会社 排尿障害改善剤
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one

Also Published As

Publication number Publication date
CA2228314A1 (en) 1997-02-20
DE19529102A1 (de) 1997-02-13
JP2000501698A (ja) 2000-02-15
EP0843553A1 (en) 1998-05-27
EA199800192A1 (ru) 1999-06-24
HUP0104619A2 (hu) 2002-04-29
AU6702596A (en) 1997-03-05
WO1997005876A1 (en) 1997-02-20
HUP0104619A3 (en) 2002-06-28

Similar Documents

Publication Publication Date Title
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
ZA983451B (en) Substituted imidazoles useful in the treatment of inflammatory diseases.
AU2639695A (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
ZA200108413B (en) Use of glycosyceramide synthesis inhibitors in therapy.
HK1000697A1 (en) Use of droloxifene for the treatment of cardiovascular diseases
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU5845099A (en) Use of (pex) in the treatment of metabolic bone diseases
NO994165D0 (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
HK1026096A1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
HUP0200738A3 (en) Method of the treatment of incontinence
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
ZA966698B (en) Use of PDE inhibitors in the treatment of urinary bladder diseases.
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
GB9922710D0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
EP1330271A4 (en) USE OF TRANSCRIPTION FACTORS FOR THE TREATMENT OF INFLAMMATION AND OTHER DISEASES
IL162776A0 (en) 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
AU7750794A (en) Use of hydroxychloroquine for treatment of graft-versus-host disease
IL115887A0 (en) Pharmaceutical compositions for the treatment of urinary bladder dysfunctions
HUP9800272A3 (en) Use of penciclovir for the treatment of human herpes-virus-8